AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02913066 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S-1 concurrent radiotherapy
Description: Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~33 planning target volume times, 60\~66 Gray/28\~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1\~ 14 days, 21 days for a cycle.
Study NCT02913066 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: S-1 plus Cisplatin concurrent radiotherapy
Description: Radiotherapy 60\~66 Gray/28\~33 times (50.4\~60 Gray /28\~30 planning target volume times, Gross tumor volume of primary tumor60\~66 Gray/28\~33), synchronous chemotherapy S-1 70 mg/m2 1\~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1\~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1\~ 14 days, plus cisplatin 25mg/m2 1\~ 4 days, 21 days for a cycle.
Study NCT05197361 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive coronary physiology
Description: Estimation of guide-wire coronary physiology parameters
Study NCT02615236 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: perineal ultrasound
Description: transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
Study NCT02615236 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical diagnosis
Description: diagnosis of OASIS clinically
Study NCT03076541 — intervention group
Intervention type: DEVICE
Intervention: standard 24-h ambulatory polysomnography
Description: A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
Study NCT00915135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and Placebo (25 possible combinations total)
Description: Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon 16 mg, tablets, orally over two nights~Ramelteon 32 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights
Study NCT01438125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MF-4181
Description: Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
Study NCT01438125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard surgical wound closure
Description: Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
Study NCT03516643 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shockwave Myocardial Revascularization
Description: extracorporeal shockwave in ischemic area evaluated by SPECT
Study NCT02207725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet
Study NCT02207725 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03408275 — intervention group
Intervention type: OTHER
Intervention: None - observational
Description: None - observational
Study NCT01718093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: up to 50 mg twice a day
Study NCT01718093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: up to 1000 mg twice a day
Study NCT01718093 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin + Metformin
Description: up to 50/1000 mg twice a day
Study NCT01568268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
Study NCT01568268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control group
Description: placebo intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
Study NCT01578863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention program for obese children
Description: The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
Study NCT03484455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic machine perfusion
Description: Organ Recovery Systems LifePort® Liver Transporter (LLT) System and Vasosol® Machine Perfusion Solution
Study NCT03484455 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Static cold storage
Description: Static cold storage (standard of care)
Study NCT00336141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suberoylanilide hydroxamic acid
Description: 400 mg QD (every day) for five days, followed by 9 days of no vorinostat
Study NCT03725839 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Interface
Description: F\&P Interface to be used for OSA therapy
Study NCT01520402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
Study NCT02878928 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IDgenetix Neuropsychiatric Test Panel
Description: The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
Study NCT02819102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX7353 and probes
Study NCT02600884 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Families Talking Together Plus (FTT+HPV)
Description: Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
Study NCT02600884 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief motivational interviewing (BMI)
Description: Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
Study NCT04606095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: EEG
Description: EEG with QST (evoked Pain and Visual Stimulation Assessment)
Study NCT04606095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: EEG
Description: EEG with QST (evoked Pain and Visual Stimulation Assessment)
Study NCT04606095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuroimaging EEG/fMRI
Description: This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then will return to the fMRI scanner for a few additional scans.
Study NCT04606095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Neuroimaging EEG/fMRI
Description: This will be done to monitor areas of the brain that are involved in thinking and processing pain. The scanner stimulates the brain to send out signals that will be recorded and analyzed. Additionally, during the MRI the participants brain's electrical activity with will be measured with an EEG machine for part of the MRI. About halfway through the scan, participants will have the EEG equipment removed and then will return to the fMRI scanner for a few additional scans.
Study NCT04606095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)
Study NCT03522948 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief intervention with text messaging to reduce sexual risk and heavy drinking among MSM
Description: Combines a brief in-person motivational intervention with personalized cognitive counseling elements and 4 weeks of personalized text messaging to support goals related to sexual risk behavior and alcohol use
Study NCT03713138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flaxseed powder
Description: Three different quantities of flax seed powder were intervened to the subjects. One group was given 15 grams of flax seed a day. Second group was given 20 grams and third group was given 25 grams off lax seed a day.
Study NCT03341507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: classical laryngoscopy
Description: the laryngoscopy with the McIntosh laryngoscope performed prior the use of rigid tube and the Cormack-Lehane glottis visualisation noted.
Study NCT03341507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rigid tube for laryngoscopy
Description: the view of glottis achieved with the rigid tub for laryngoscopy and tracheal intubation with an elastic gum bougie performed
Study NCT04606095 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)
Study NCT04606095 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)
Study NCT04606095 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS treatments
Description: HD-tDCS treatments (5 active and 5 sham)
Study NCT01982435 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
Study NCT01982435 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ranibizumab
Description: Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
Study NCT02676401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Low
Study NCT02676401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 Middle
Study NCT02676401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995 High
Study NCT03202043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose vegetable juice
Description: High dose (13 fl oz) vegetable juice
Study NCT03202043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium dose vegetable juice
Description: Medium dose (10 fl oz) vegetable juice
Study NCT03202043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose vegetable juice
Description: Low dose (5.5 fl oz) vegetable juice
Study NCT03202043 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control bottled water
Description: Control (12 fl oz) bottled water
Study NCT03237273 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HEAD-US scoring system
Description: HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
Study NCT02294656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab,
Description: Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
Study NCT02294656 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone acetonide
Description: Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
Study NCT03291509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Conference Meetings
Description: Individual video conferencing with a health educator using an iPad.
Study NCT03291509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-person Meetings
Description: Individual face-to-face (FTF) meetings with a health educator.
Study NCT03291509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Stop Light Diet
Description: Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
Study NCT03291509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Stop Light Diet
Description: Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
Study NCT03291509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
Study NCT03291509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity
Description: Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
Study NCT01234636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Placebo oil of 4g/day
Study NCT01234636 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oil
Description: Placebo oil of 4g/day
Study NCT02374918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mTBI wavelength-1 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning
Study NCT02374918 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: mTBI wavelength-2 bright light
Description: 6 weeks of daily light exposure, 30 minutes per morning
Study NCT02374918 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HC wavelength-1 bright light
Description: 30 minutes of light exposure
Study NCT02374918 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: HC wavelength-2 bright light
Description: 30 minutes of light exposure
Study NCT02046421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone
Description: Given PO
Study NCT02046421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT02046421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT02046421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT02046421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01105650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously, 25 mg/m\^2, days -6 through -2 (5 days).
Study NCT01105650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously, 60 mg/kg, days -5 and -4.
Study NCT01105650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
Study NCT01105650 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural killer cells
Description: Administered by infusion over less than 1 hour, no more than 8.0 x 10\^7 cells/kg will be given.
Study NCT01105650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m\^2 3 times per week for 6 doses).
Study NCT01105650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
Study NCT01105650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Administered intravenously (IV) 1 mg/kg Days -2 to +9
Study NCT01105650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m\^2 3 times per week for 6 doses).
Study NCT01236963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Essential oils mouthrinse
Description: Commercial mouthrinse with manufacturer's use indications
Study NCT03665844 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartSleep Boost On
Description: SmartSleep device can be configured to two different settings. SmartSleep Boost On setting provides soft audio tones during the night.~It's a non-invasive portable light weight device designed to stimulate deep slow wave sleep (SWS).
Study NCT03665844 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SmartSleep Boost Off
Description: SmartSleep device can be configured to two different settings. SmartSleep Boost Off provides no audio tones.
Study NCT01916005 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Study NCT01236963 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Floss
Study NCT03456830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-177
Description: ALLN-177 7,500 units (2 capsules), orally, with each meal/snack, 3 to 5 times per day for 28 days
Study NCT03456830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 capsules, orally, with each meal/snack, 3 to 5 times per day for 28 days
Study NCT00600223 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires and standardized, digital voice recording
Description: Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
Study NCT03104309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Levonorgestrel intrauterine system
Description: Levonorgestrel intrauterine system for adenomyosis
Study NCT02376322 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
Study NCT00908089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab
Description: methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
Study NCT00908089 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
Description: methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
Study NCT02656576 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tonsil Biopsy
Description: Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
Study NCT02656576 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Smear
Description: The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
Study NCT01567358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 100mg/vial
Study NCT01567358 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: 100mg/vial